Knopp Biosciences
Business Services · Pennsylvania, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2100 Wharton St Ste 615, Pittsburgh, Pen...Phone Number
(412) 488-1776Website
www.knoppbio.comRevenue
$5.2 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Knopp Biosciences
Knopp Biosciences LLC is a privately held company focused on drug discovery for immunological and neurological diseases. The company is developing dexpramipexole for eosinophilic asthma and has a Kv7 platform for epilepsy treatments, which is being advanced by Biohaven Pharmaceuticals. Founded in 2004, Knopp manages a portfolio of equity securities and product royalties. Their investor portal will provide updates and proprietary information to members starting Spring 2023.Explore more
Knopp Biosciences Org Chart
FL
Vice President and General Counsel
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Knopp Biosciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Knopp Biosciences has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Knopp Biosciences has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Knopp Biosciences recently announced quarterly report
Click to see if Knopp Biosciences had a recent Job posting/layoffs
Product Launch: Get notified when Knopp Biosciences launches new products
Check out if Knopp Biosciences is spiking on competitors!
Website visits: Recent activity has been detected on your website
Knopp Biosciences, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Knopp Biosciences
Recommended Actions
Find VP level buyers at Knopp Biosciences
Find more new buyers
Compare Similar Companies to Knopp Biosciences
Compare insights from companies similar to Knopp Biosciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
<$5M
1-10
Private
-
2011
Mark KlevenSenior Vice President, Scientific Operations, Chief Operating Officer
Company Profile Activity
Activity Insights
Knopp Biosciences is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Knopp Biosciences is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Knopp Biosciences.
Knopp Biosciences financials insights
Gather financial insights about Knopp Biosciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2006
Series A
$10M
2008
Series B
$10M
2012
Private Equity
$14.9M
2014
Debt
$23M
2020
Debt
$350K
Series C
$14M
Knopp Biosciences Tech Stack
A closer look at the technologies used by Knopp Biosciences
See more technologies
Knopp Biosciences News & Media
Knopp Biosciences Presents New Phase 2 Data at AAAAI 2022 Demonstrating That Oral Dexpramipexole Improves Airflow Obstruction as Measured by Forced Expiry Volume (FEV1), Largely Through Its Effect on Forced Vital Capacity (FVC)
PITTSBURGH--(BUSINESS WIRE)--Knopp Biosciences LLC today reported further clinical data from its Phase 2 Exhale trial demonstrating oral dexpramipexole improves airflow obstruction in asthma as measured by FEV1, largely through its effect on FVC. Change in FVC was the dominant contributor to increases in FEV1, which suggests that by lowering eosinophils in the airway lumen, dexpramipexole may act to decrease mucus plugging and air trapping in small airways. As previously reported, dexpramipexolBiohaven Acquires Kv7 Ion Channel Platform for the Treatment of Epilepsy and Other Neurologic Disorders From Channel Biosciences, a Subsidiary of Knopp Biosciences
NEW HAVEN, Conn., Feb. 25, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the "Company" or "Biohaven") announced today that it has entered into a definitive agreement to acquire Channel Biosciences, LLC, a subsidiary of Knopp Biosciences LLC, and its Kv7...Knopp Biosciences NIH-funded Pain Program Advances to Third Year of HEAL Award to Discover Non-Opioid Treatments for Chronic Pain
PITTSBURGH--(BUSINESS WIRE)--Knopp Biosciences LLC today announced that it was awarded a third year of research funding by the National Institutes of Health (NIH) to advance the development of its novel non-opioid therapies for the treatment of chronic pain. The project is funded by the NIH Helping to End Addiction Long-term Initiative (NIH HEAL Initiative), which aims to improve treatments for chronic pain, curb the rates of opioid use disorder and overdose, and achieve long-term recoveryKnopp Biosciences Presents New Phase 2 Data at ERS 2021 Demonstrating that Reduction in Eosinophil Count by Dexpramipexole Significantly Correlates with Improvement in Lung Function
PITTSBURGH--(BUSINESS WIRE)--Knopp Biosciences LLC today reported further clinical and biomarker data demonstrating that reduction in eosinophil count by oral dexpramipexole significantly correlated with improved lung function in the positive Phase 2 EXHALE trial of dexpramipexole in patients with moderate-to-severe eosinophilic asthma. The data were presented in a late-breaking abstract session at the European Respiratory Society International Congress 2021. Eosinophils, a type of white-blood
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Knopp Biosciences
Sign Up For FreeTo access detailed company insights
Knopp Biosciences LLC is a privately held company focused on drug discovery for immunological and neurological diseases. The company is developing dexpramipexole for eosinophilic asthma and has a Kv7 platform for epilepsy treatments, which is being advanced by Biohaven Pharmaceuticals. Founded in 2004, Knopp manages a portfolio of equity securities... Read More
